Industry Veteran to Lead and Grow MaxCyte’s Global Presence
Gaithersburg, MD, October 15, 2014 – MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, is pleased to announce the appointment of industry veteran Tom Ross to the position of Executive Vice President of Global Sales. In this role, Mr. Ross will serve a member of the executive management team and an officer of the company. In his day-to-day role, he will oversee a global sales force.
Mr. Ross comes to MaxCyte with more than 20 years of experience in Biotechnology. Most recently, Mr. Ross was Senior Vice President of Commercial Operations at OpGen®. His previous experience includes Director of Operations at Life Technologies; Vice President of Sales at several biotechnology companies including Digene Corporation, Qiagen, and Meso Scale Discovery; and Chief Commercial Officer at Predictive Biosciences.
“This is an exciting time for MaxCyte,” stated Doug Doerfler, President and CEO of MaxCyte, Inc. “Tom’s experience and leadership skills will be a great asset as we grow the business while continuing to provide support and solutions to our customers around the world.”
“I’m delighted to be part of the MaxCyte team,” stated Mr. Ross. “I look forward to working with pharmaceutical and biotechnology companies alike to show them how the MaxCyte STX® Scalable Transfection System can enable them to work directly in their manufacturing cell line to generate the most relevant data for candidate selection, saving time and resources and accelerating market release. It is truly an enabling technology.”
Mr. Ross will be based in MaxCyte’s corporate headquarters in Gaithersburg, MD.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information visit /
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter